GBS/CIDP Foundation International: Our Commitment
The Foundation began over 30 years ago as a support group for patients & families impacted by Guillain‐Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) or any of the variants that exist. Since then, our commitment has been to provide support to those affected by these disorders so that every patient obtains an early diagnosis, proper treatment & the opportunity for a full recovery. More >>
Topics of Interest
Friday, October 31, 2014 - Sunday, November 2, 2014 at Disney's Coronado Springs Resort and Convention Center in Orlando, Florida.
Hotel information and registration materials will be mailed in the spring. If you are not on our mailing list and would like to be, please email your request to email@example.com.
Neuropathy Action Foundation and GBS/CIDP Foundation International Launch Multifocal Motor Neuropathy (MMN) Campaign to Raise Awareness of Rare Neurological Condition
The Neuropathy Action Foundation (NAF) and the GBS/CIDP Foundation International (GBS/CIDP) today announced the launch of a joint nationwide campaign to raise awareness of Multifocal Motor Neuropathy (MMN), a rare and incurable neurological condition in which multiple motor nerves are attacked by the immune system.
GBS/CIDP Foundation International announces the establishment of the Benson Fellowship to fund Peripheral Inflammatory Neuropathy Fellowships
The GBS/CIDP Foundation International has established the Benson Fellowship to fund Peripheral Neuropathy Fellowships in honor of Robert Benson, a survivor of Guillain-Barre' Syndrome, and his wife Estelle Benson. The Foundation voted to endow over $1,600,000 of its financial resources to initially fund the Fellowship. More >>
Recently, one of the physicians on the GBS/CIDP Foundation Medical Advisory Board saw a man who carried the diagnosis of CIDP for 2 years. During that time, he received IVIg monthly for 18 months then plasmapheresis monthly for five months without any clinical improvement. He went to a GBS/CIDP Foundation Center of Excellence where it was determined that he did not have CIDP, as the diagnosis was made on incorrectly interpreted nerve conduction studies in the wrong clinical context. The patient calculated that the cost of his treatments was over $400,000. Unfortunately, this is not uncommon. More >>
Richard J. Barohn, MD, Professor and Chair Department of Neurology at the University of Kansas Medical Center, and a member of the GBS/CIDP Foundation International Medical Advisory Board gave a presentation to the Harris County Neurological Society in November – "CIDP: Diagnosis and Treatment". Sit back and watch the video (an hour long) and hear from one of the leading experts on CIDP in the world. Share it with your neurologist.
CSL Behring is currently recruiting CIDP patients for a clinical trial. Click for full access to view article.